Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy

Epilepsia

Volumn 39, Issue 8, 1998, Pages 868-873

  Samara, E E ^a   Gustavson, L E ^a   El Shourbagy, T ^a   Locke, C ^a   Granneman, G R ^a   Sommerville, K W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Epilepsy; Pharmacokinetics; Population; Tiagabine

Indexed keywords

TIAGABINE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POPULATION RESEARCH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MODELS, STATISTICAL; NIPECOTIC ACIDS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING;

EID: 0031849905     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01182.x     Document Type: Article

References (12)

1. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
2. Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatirc patients with complex partial seizures. Neurology 1997;48:1032-7.
3. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995;22:221-6.
4. Sachdeo RC, Biton V, Boellner SW, et al. Long term safety of tiagabine HCl. Epilepsia 1995;36(suppl 4):55.
5. Gustavson LE, Chu S-y. High performance liquid Chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr Biomed Appl 1992;574:313-8.
6. Beal SL, Sheiner LB. NONMEM users' guide. San Francisco: NONMEM Project Group, University of California, 1989.
7. Samara E, Granneman R. Role of population pharmacokinetics in drug development - a pharmaceutical industry perspective. Clin Pharmacokinet 1997;32:294-312.
8. Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs, Clin Pharmacol Ther 1985;38:481-7.
9. Tanigawara Y, Hori R. Population approach in post marketing dose adjustment. In: Rowland M, Aarons L, ed. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 223-32.
10. Yukawa E, Higushi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chem Pharm Bull 1990;38:1973-6.
11. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-65.
12. Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A. Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. Clin Pharmacol Ther 1997;62:426-35.